Bevacizumab biosimilar (CTTQ Pharma) | Interleukin Related interleukin-related.com

Product Name :
Bevacizumab biosimilar (CTTQ Pharma)

Search keywords :
Bevacizumab

drugId :
null

Target Vo:
Vascular endothelial growth factor A

Target Vo Short Name :
VEGFA

Moa_Name:
Vascular endothelial growth factor A inhibitors

First Approval Country :
Mainland China

First Approval Date Filter:
2023

Origin Company_Name :
Jiangsu Chia Tai-Tianqing Pharmaceutical Co Ltd

Active Company_Name :
Jiangsu Chia Tai-Tianqing Pharmaceutical Co Ltd

Active Indication_Name:
Carcinoma, Non-Small-Cell Lung

In Active Indication_Name:
Small Cell Lung Carcinoma

Termination Status :

China Termination Status :

Highest Status:
Approved

China Highest Status:
Approved

Antibodies are immunoglobulins secreted by effector lymphoid B cells into the bloodstream. Antibodies consist of two light peptide chains and two heavy peptide chains that are linked to each other by disulfide bonds to form a “Y” shaped structure. Both tips of the “Y” structure contain binding sites for a specific antigen. Antibodies are commonly used in medical research, pharmacological research, laboratory research, and health and epidemiological research. They play an important role in hot research areas such as targeted drug development, in vitro diagnostic assays, characterization of signaling pathways, detection of protein expression levels, and identification of candidate biomarkers.
Related websites: https://www.medchemexpress.com/antibodies.html
Popular product recommendations:
DGAT1 Antibody supplier
LC3B Rabbit pAb In stock
CD81 Antibody: CD81 Antibody is a non-conjugated and Rabbit origined monoclonal antibody about 26 kDa, targeting to CD81. It can be used for WB,IHC-F,IHC-P,ICC/IF assays with tag free, in the background of Human, Mouse.

Author: Interleukin Related

Related Posts